Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short-term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport and Dysport NG) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport NG Following Repeated Treatments of Subjects With Cervical Dystonia

Next Previous
Trial Profile

A Phase III, Randomised, Double-blind and Open Label Phase, Active and Placebo Controlled Study Comparing the Short-term Efficacy of Two Formulations of Clostridium Botulinum Type A Toxin (Dysport and Dysport NG) to Placebo, and Assessing the Short and Long Term Efficacy and Safety of Dysport NG Following Repeated Treatments of Subjects With Cervical Dystonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Torticollis
  • Focus Registrational; Therapeutic Use
  • Sponsors Ipsen

Most Recent Events

  • 22 Sep 2021 Results assessing meta-analysis of patient-level data from four randomized, placebo-controlled studies (Truong et al 2005 & 2010, NCT01261611, NCT01753310) of AboBoNT-A 500U and three associated open-label extension studies were presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
  • 22 Apr 2021 Results of meta analyses of patient level data from four randomized, placebo controlled studies (Truong et al 2005 & 2010, NCT01261611, NCT01753310) of AboBoNT-A 500U and three associated open-label extension studies presented at the 73rd Annual Meeting of the American Academy of Neurology
  • 14 Nov 2014 Results were presented at the Annual Assembly of the Academy of Physical Medicine and Rehabilitation (AAPM&R) according to an Ipsen media release reporting the results.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top